Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene Expression Analysis of Hypertrophic and Dilated Cardiomyopathy Associated TPM1 mutations in Engineered Heart Tissues

ABSTRACT: Gene Expression Analysis of Hypertrophic and Dilated Cardiomyopathy Associated TPM1 mutations in Engineered Heart Tissues

PROVIDER: PRJNA1056285 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27335607_1.fastq.gz	Fastqsanger.gz
	SRR27335607_2.fastq.gz	Fastqsanger.gz
	SRR27335608_1.fastq.gz	Fastqsanger.gz
	SRR27335608_2.fastq.gz	Fastqsanger.gz
	SRR27335609_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Cardiac Proteomic Profiling in Hypertrophic and Dilated Cardiomyopathy

Project description:Hypertrophic cardiomyopathy and dilated cardiomyopathy are different diseases with distinct clinical manifestations, and the confounding pathogenic mechanisms behind them remains unclear. The purpose of this study was to find out the crucial proteins and pathways in severe cardiomyopathy patients, through the proteomic technology in myocardial tissues.

2022-11-21 | PXD038255 |

Gene Expression Analysis of Hypertrophic and Dilated Cardiomyopathy Associated TPM1 mutations in Engineered Heart Tissues

Project description:Hypertrophic and dilated cardiomyopathies (HCM and DCM, respectively) are inherited disorders that may be caused by mutations to the same sarcomeric protein but have completely different clinical phenotypes. The precise mechanisms by which point mutations within the same gene bring about phenotypic diversity remain unclear. Our objective has been to develop a mechanistic explanation of diverging phenotypes in two TPM1 mutations, E62Q (HCM) and E54K (DCM). Drawing on data from the literature and novel experiments with stem cell-derived cardiomyocytes expressing the TPM1 mutations of interest, we constructed computational simulations that provide plausible explanations of the distinct muscle contractility caused by each variant. In E62Q, increased calcium sensitivity and hypercontractility was explained most accurately by a reduction in effective molecular stiffness of tropomyosin and alterations in its interactions with the actin thin filament that favor the ‘closed’ regulatory state. By contrast, the E54K mutation appears to act via long-range allosteric interactions to increase the association rate of the C-terminal troponin I mobile domain to tropomyosin/actin. These mutation-linked molecular events produce diverging alterations in gene expression that can be observed in human engineered heart tissues. Modulators of myosin activity confirm our proposed mechanisms by rescuing normal contractile behavior in accordance with predictions.

2024-12-19 | GSE251993 | GEO

Dilated Cardiomyopathy

Project description:Dilated Cardiomyopathy

| PRJNA1006418 | ENA

Human iPSC-derived cardiomyocyte from a patient with dilated phase of hypertrophic cardiomyopathy

Project description:Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder characterized by ventricular wall hypertrophy and diastolic dysfunction. Most patients with HCM are often a slowly progressive disease and may be asymptomatic; however, some progress to the dilated phase of HCM (D-HCM), and have a poorer prognosis. This study established disease-specific human induced pluripotent stem cells (iPSCs) from a patient with D-HCM harboring a truncating mutation in MYBPC3, and compared transcriptomes of iPSCs-derived cardiomyocytes between healthy control and D-HCM.

2025-04-06 | GSE263980 | GEO

Transcription profiling of human heart with heart failure due to ischemic cardiomyopathy or dilated cardiomyopathy

Project description:End stage heart failure due to ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) have similar characteristics, enlargement of the ventricles, relatively thin-walled ventricle, which leads to a limited contraction force and blood loading. Nevertheless, the response for present therapeutics is very variable and the prognosis is still very bad for ICM and DCM in general. Thus, the ability to differentiate the etiologies of heart failure based structural and physiological changes of the heart would be a step forward to enhance the specificity and the success of given therapy.

2007-10-31 | E-CVDE-1 | biostudies-arrayexpress

Dilated cardiomyopathy vs Myocarditis

Project description:Dilated cardiomyopathy vs Myocarditis

| PRJNA493608 | ENA

Transcription profiling of wild type and delK210 cTnT knock-in mouse heart to study dilated cardiomyopathy

Project description:Changes in the gene expression in the heart of knock-in mouse model of dilated cardiomyopathy caused by delK210 mutation in cardiac troponin T.

2008-09-04 | E-MEXP-1340 | biostudies-arrayexpress

Human Hypertrophic Cardiomyopathy mRNA Profiling.

Project description:Cardiac biopsies were obtained from hypertrophic cardiomyopathy (HCM) patients and controls and subjected to mRNA profiling.

2024-11-12 | GSE249925 | GEO

Differential gene expressions in the heart of hypertrophic cardiomyopathy patients

Project description:Differential gene expressions were constructed through expression profiling of a total of 20,127 genes in the heart tissue of hypertrophic cardiomyopathy patients, then 1799 significant differential genes were filtered based on the criteria (p<0.05 and fold change > 1.5), respectively.

2016-11-10 | GSE89714 | GEO

Human Hypertrophic Cardiomyopathy mRNA Profiling.

Project description:Human Hypertrophic Cardiomyopathy mRNA Profiling.

| PRJNA1051135 | ENA